Xilio Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Xilio Therapeutics, Inc. (XLO) reported Basic Shares Outstanding (Weighted Average) of 19.40 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-12
- Xilio Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 19.40M shares, a 181.67% increase year-over-year.
- Xilio Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 16.35M shares, a 206.38% increase year-over-year.
- Xilio Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was -282.58M shares.
- Xilio Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 144.11M shares, a 127.06% increase year-over-year.
- Xilio Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 8.36M shares, a 118.70% increase from fiscal 2024.
- Xilio Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 3.82M shares, a 86.10% decline from fiscal 2023.
- Xilio Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 27.50M shares, a 0.38% increase from fiscal 2022.
- Xilio Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 27.39M shares, a 388.59% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month | Weighted Average Number of Shares Outstanding, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 19.40M shares 10-Q · filed 2026-08-12 | 17.88M shares 10-Q · filed 2026-08-12 | -82.28M shares derived: average of 3 quarters · filed 2026-08-12 | -25.68M shares derived: average of 4 quarters · filed 2026-08-12 | |||
| 2026-03-31 | 16.35M shares 10-Q · filed 2026-05-12 | -133.12M shares derived: average of 2 quarters · filed 2026-05-12 | -40.71M shares derived: average of 3 quarters · filed 2026-05-12 | -28.81M shares derived: average of 4 quarters · filed 2026-08-12 | |||
| 2025-12-31 | -282.58M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -69.24M shares derived: average of 2 quarters · filed 2026-03-23 | -43.86M shares derived: average of 3 quarters · filed 2026-08-12 | 8.36M shares 10-K · filed 2026-03-23 | |||
| 2025-09-30 | 144.11M shares 10-Q · filed 2025-11-13 | 75.50M shares derived: average of 2 quarters · filed 2026-08-12 | 105.34M shares 10-Q · filed 2025-11-13 | 5.58M shares derived: average of 4 quarters · filed 2026-08-12 | |||
| 2025-06-30 | 6.89M shares 10-Q · filed 2026-08-12 | 96.45M shares 10-Q · filed 2025-08-14 | 6.12M shares 10-Q · filed 2026-08-12 | 85.63M shares 10-Q · filed 2025-08-14 | -40.59M shares derived: average of 3 quarters · filed 2026-08-12 | -14.58M shares derived: average of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | 5.34M shares 10-Q · filed 2026-05-12 | 74.70M shares 10-Q · filed 2025-05-08 | -64.33M shares derived: average of 2 quarters · filed 2026-05-12 | -21.73M shares derived: average of 3 quarters · filed 2026-05-12 | -1.86M shares derived: average of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | -134.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -35.27M shares derived: average of 2 quarters · filed 2026-03-23 | -4.26M shares derived: average of 3 quarters · filed 2026-03-23 | 3.82M shares 10-K · filed 2026-03-23 | 53.51M shares 10-K · filed 2025-03-11 | ||
| 2024-09-30 | 63.47M shares 10-Q · filed 2025-11-13 | 60.61M shares derived: average of 2 quarters · filed 2025-11-13 | 49.76M shares 10-Q · filed 2025-11-13 | 44.17M shares derived: average of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | 57.76M shares 10-Q · filed 2025-08-14 | 42.84M shares 10-Q · filed 2025-08-14 | 37.74M shares derived: average of 3 quarters · filed 2025-08-14 | 35.19M shares derived: average of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | 27.91M shares 10-Q · filed 2025-05-08 | 27.74M shares derived: average of 2 quarters · filed 2025-05-08 | 27.66M shares derived: average of 3 quarters · filed 2025-05-08 | 27.62M shares derived: average of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | 27.56M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 27.54M shares derived: average of 2 quarters · filed 2025-03-11 | 27.52M shares derived: average of 3 quarters · filed 2025-03-11 | 27.50M shares 10-K · filed 2025-03-11 | |||
| 2023-09-30 | 27.52M shares 10-Q · filed 2024-11-07 | 27.50M shares derived: average of 2 quarters · filed 2024-11-07 | 27.48M shares 10-Q · filed 2024-11-07 | 27.46M shares derived: average of 4 quarters · filed 2024-11-07 | |||
| 2023-06-30 | 27.47M shares 10-Q · filed 2024-08-08 | 27.45M shares 10-Q · filed 2024-08-08 | 27.44M shares derived: average of 3 quarters · filed 2024-08-08 | 27.43M shares derived: average of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | 27.43M shares 10-Q · filed 2024-05-14 | 27.42M shares derived: average of 2 quarters · filed 2024-05-14 | 27.42M shares derived: average of 3 quarters · filed 2024-05-14 | 27.41M shares derived: average of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | 27.42M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | 27.41M shares derived: average of 2 quarters · filed 2024-04-01 | 27.40M shares derived: average of 3 quarters · filed 2024-04-01 | 27.39M shares 10-K · filed 2024-04-01 | |||
| 2022-09-30 | 27.40M shares 10-Q · filed 2023-11-09 | 27.39M shares derived: average of 2 quarters · filed 2023-11-09 | 27.38M shares 10-Q · filed 2023-11-09 | 25.59M shares derived: average of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | 27.38M shares 10-Q · filed 2023-08-14 | 27.38M shares 10-Q · filed 2023-08-14 | 24.99M shares derived: average of 3 quarters · filed 2023-08-14 | 18.93M shares derived: average of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | 27.37M shares 10-Q · filed 2023-05-09 | 23.79M shares derived: average of 2 quarters · filed 2023-05-09 | 16.12M shares derived: average of 3 quarters · filed 2023-05-09 | 12.27M shares derived: average of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | 20.22M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | 10.49M shares derived: average of 2 quarters · filed 2023-03-02 | 7.24M shares derived: average of 3 quarters · filed 2023-03-02 | 5.61M shares 10-K · filed 2023-03-02 | |||
| 2021-09-30 | 763.87K shares 10-Q · filed 2022-11-09 | 750.17K shares derived: average of 2 quarters · filed 2022-11-09 | 736.42K shares 10-Q · filed 2022-11-09 | 717.23K shares derived: average of 4 quarters · filed 2022-11-09 | |||
| 2021-06-30 | 736.47K shares 10-Q · filed 2022-08-09 | 722.42K shares 10-Q · filed 2022-08-09 | 701.68K shares derived: average of 3 quarters · filed 2022-08-09 | 679.42K shares derived: average of 4 quarters · filed 2022-08-09 | |||
| 2021-03-31 | 708.26K shares 10-Q · filed 2022-05-12 | 684.28K shares derived: average of 2 quarters · filed 2022-05-12 | 660.41K shares derived: average of 3 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | 660.29K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | 636.48K shares derived: average of 2 quarters · filed 2022-03-01 | 523.79K shares 10-K · filed 2022-03-01 | ||||
| 2020-09-30 | 612.66K shares 10-Q · filed 2021-12-02 | 478.28K shares 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |